These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 17471245

  • 1. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV.
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. New cytokine targets in inflammatory rheumatic diseases.
    Connell L, McInnes IB.
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
    Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X.
    Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
    [Abstract] [Full Text] [Related]

  • 8. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
    Taylor RP, Lindorfer MA.
    Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
    Eklund KK.
    Immunol Rev; 2007 Jun; 217():38-52. PubMed ID: 17498050
    [Abstract] [Full Text] [Related]

  • 11. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H, Nishimoto N.
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
    Beresford MW, Baildam EM.
    Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
    [Abstract] [Full Text] [Related]

  • 14. Antibody production: polyclonal-derived biotherapeutics.
    Newcombe C, Newcombe AR.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar 15; 848(1):2-7. PubMed ID: 16893686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR.
    Int Immunopharmacol; 2009 Jan 15; 9(1):10-25. PubMed ID: 19000786
    [Abstract] [Full Text] [Related]

  • 18. Biological therapies in rheumatic diseases.
    Conti F, Ceccarelli F, Massaro L, Cipriano E, Di Franco M, Alessandri C, Spinelli FR, Scrivo R.
    Clin Ter; 2013 Jan 15; 164(5):e413-28. PubMed ID: 24217844
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A.
    Scand J Immunol; 2007 Oct 15; 66(4):476-83. PubMed ID: 17850593
    [Abstract] [Full Text] [Related]

  • 20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA, Hu P, Epstein AL.
    Handb Exp Pharmacol; 2008 Oct 15; (181):291-328. PubMed ID: 18071951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.